Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
External Partnership Proposals is sponsored by The High Q Foundation Inc.. This program facilitates collaboration with the biopharmaceutical community to evaluate preclinical or clinical phase ligands that may be useful for target validation or mechanistic studies in Huntington's disease. CHDI can enter into Compound Testing Agreements (CTA) to fund and validate third-party molecules using their network of specialized contract research organizations (CROs), while the partner retains intellectual property rights.
Geographic focus: Global
Focus areas: Huntington's Disease, Ligand evaluation, Target validation, Preclinical and clinical proof-of-concept testing, Drug discovery
Official opportunity description and requirements excerpt:
External Partnership Proposals | CHDI Foundation Accelerating Therapeutic Development for Huntington's Disease Research tools & reagents Data sharing & infomatics Preclinical informatics: HDinHD External Partnership Proposals Independent Statistical Standing Committee Clinical outcomes: Rating scales Field guide to HD mouse models HD Therapeutics Conference Data, Reagents, and Biomaterials Sharing Policy Reimbursement of Publication Costs Financial Support for Conferences, Meetings, or Workshops Research tools & reagents Data sharing & infomatics Preclinical informatics: HDinHD External Partnership Proposals Independent Statistical Standing Committee Clinical outcomes: Rating scales Field guide to HD mouse models HD Therapeutics Conference Data, Reagents, and Biomaterials Sharing Policy Reimbursement of Publication Costs Financial Support for Conferences, Meetings, or Workshops External Partnership Proposals External Partnership Proposals CHDI has an External Partnerships effort that is interested in learning about preclinical or clinical phase ligands from the biopharmaceutical community that may be useful for target and/or mechanistic validation studies for Huntingdon’s disease with the potential to be disease-modifying. If you have a compound of interest and would like to collaborate with CHDI to evaluate it in an HD context for proof of concept, please submit a non-confidential package for our science directors to review. CHDI’s External Partnerships team will determine whether there is interest and, if so, will work with you to develop a mutually agreeable plan. The type of a potential collaboration depends on the compound of interest and the nature of your request. CHDI does not typically provide direct funding for preclinical evaluation of compounds. We can, under some circumstances, enter into a compound testing agreement (CTA) that allows us to validate the effect of third-party molecules with our contract research organization (CRO) colleagues. We have a wide variety of validated assays available, some of them proprietary to CHDI, including generic ADMET assays, PK/PD endpoints, biomarker assays, HD-specific cellular assays, and several phenotypic disease progression measures in HD animal models. All studies conducted at CROs under a CTA will be funded by CHDI and the resulting data is confidential. Your organization retains ownership of all intellectual property rights and data generated, and we typically do not ask for structures to be disclosed. Furthermore, you may opt to fund your own additional studies on any returned samples and/or animal tissues. Our External Partnerships team focuses on HD-relevant projects that are at or near the proof-of-concept stage for in vivo animal testing. CHDI has internal drug discovery programs that focus on earlier stage projects, so we do not provide funding for either external drug screening activities or optimizing compounds at the hit-to-lead stage. CHDI
Extracted from the official opportunity page/RFP to help you evaluate fit faster.
External Partnership Proposals | CHDI Foundation Accelerating Therapeutic Development for Huntington's Disease Research tools & reagents Data sharing & infomatics Preclinical informatics: HDinHD External Partnership Proposals Independent Statistical Standing Committee Clinical outcomes: Rating scales Field guide to HD mouse models HD Therapeutics Conference Data, Reagents, and Biomaterials Sharing Policy Reimbursement of Publication Costs Financial Support for Conferences, Meetings, or Workshops Research tools & reagents Data sharing & infomatics Preclinical informatics: HDinHD External Partnership Proposals Independent Statistical Standing Committee Clinical outcomes: Rating scales Field guide to HD mouse models HD Therapeutics Conference Data, Reagents, and Biomaterials Sharing Policy Reimbursement of Publication Costs Financial Support for Conferences, Meetings, or Workshops External Partnership Proposals External Partnership Proposals CHDI has an External Partnerships effort that is interested in learning about preclinical or clinical phase ligands from the biopharmaceutical community that may be useful for target and/or mechanistic validation studies for Huntingdon’s disease with the potential to be disease-modifying.
If you have a compound of interest and would like to collaborate with CHDI to evaluate it in an HD context for proof of concept, please submit a non-confidential package for our science directors to review. CHDI’s External Partnerships team will determine whether there is interest and, if so, will work with you to develop a mutually agreeable plan.
The type of a potential collaboration depends on the compound of interest and the nature of your request. CHDI does not typically provide direct funding for preclinical evaluation of compounds. We can, under some circumstances, enter into a compound testing agreement (CTA) that allows us to validate the effect of third-party molecules with our contract research organization (CRO) colleagues.
We have a wide variety of validated assays available, some of them proprietary to CHDI, including generic ADMET assays, PK/PD endpoints, biomarker assays, HD-specific cellular assays, and several phenotypic disease progression measures in HD animal models. All studies conducted at CROs under a CTA will be funded by CHDI and the resulting data is confidential.
Your organization retains ownership of all intellectual property rights and data generated, and we typically do not ask for structures to be disclosed. Furthermore, you may opt to fund your own additional studies on any returned samples and/or animal tissues. Our External Partnerships team focuses on HD-relevant projects that are at or near the proof-of-concept stage for in vivo animal testing.
Based on current listing details, eligibility includes: Biopharmaceutical and biotechnology companies. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
View foundation profile, grantmaking history, financials, and key people.
View Foundation ProfileApplication snapshot: target deadline rolling deadlines or periodic funding windows; published funding information Not specified; eligibility guidance Biopharmaceutical and biotechnology companies.
Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
CHDI has internal drug discovery programs that focus on earlier stage projects, so we do not provide funding for either external drug screening activities or optimizing compounds at the hit-to-lead stage. CHDI can provide advice and point towards a variety of resources, including HD animal model testing protocols available through our network of specialized CROs.
If you are interested in a potential collaboration to evaluate your advanced preclinical or clinical phase compound, please provide the following information: The biological rationale for efficacy in HD, The molecule’s biological profile (without disclosing the structure), A detailed non-confidential information package about the molecule(s) that will allow us to evaluate its potential for translation to the clinic.
We need to understand how advanced the molecule(s) is/are and the rationale for efficacy in HD. Please send your full contact information and non-confidential information package to . After review and evaluation, we may set up an initial exploratory call between your team and our External Partnerships team.
Please allow a few weeks for the internal review process. Frequently Asked Questions I have a clinical candidate for HD, how can I get involved with CHDI? For all clinical questions, please email our clinical group at: .
CHDI’s clinical group will liaise internally with the preclinical group to evaluate the scientific rationale and strength of the program before dedicating any significant time or resources to providing clinical advice. I‘d like feedback on my HD research, can CHDI put me in touch with an expert?
If you are looking for preclinical advice, please send your specific questions and non-confidential information package to and we will connect you to a CHDI science director with the relevant expertise. I have a novel technology that I think will advance HD therapeutic development. How can I collaborate with CHDI?
Submit a detailed non-confidential information package to and we will direct your request to the appropriate contact at CHDI. Can CHDI help place a value on an asset? CHDI does not provide valuations, investment guidance, or venture philanthropy.
Scientists, patient advocates, journalists and others are invited to contact CHDI for more information.
350 Seventh Ave, Suite 200, New York, NY 10001 6080 Center Drive, Suite 700, Los Angeles, CA 90045 155 Village Boulevard, Suite 200, Princeton, NJ 08540 CHDI is looking to hire qualified individuals for the following positions: Clinical Research Program Manager-Neuroimaging (NJ) Director, Digital Assessment (NJ) System Administrator (NJ) We are an Equal Opportunity Employer.
All persons shall have the opportunity to be considered for employment without regard to their race, color, religion, national origin, ancestry, alienage or citizenship status, age, disability, sex, marital status, veteran status, sexual orientation, genetic information or any other characteristic protected by applicable federal, state or local laws. For all job inquiries contact function show_popup_email() document.
getElementById('popup_email'). style. display="block"; function hide_popup_email() document.
getElementById('popup_email'). style. display="none"; function show_popup_terms() document.
getElementById('terms'). style. display="block"; function hide_popup_terms() document.
getElementById('terms'). style. display="none"; function show_popup_policy() document.
getElementById('policy'). style. display="block"; function hide_popup_policy() document.
getElementById('policy'). style. display="none"; We appreciate any comments or questions on this page—our goal is to make this concise and helpful.
We appreciate any comments or questions on this page—our goal is to make this concise and helpful. Receive spam-free updates from the Huntington's disease research community. Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 3.
0 Unported License . Receive spam-free updates from the Huntington's disease research community. We reserve the right, in our sole discretion, without any obligation or notice requirement, to suspend or deny your access to the Website for any reason, including for scheduled or unscheduled maintenance, upgrades, improvements or corrections.
You may not attempt to gain unauthorized access to the Website, through hacking, password mining or any other means to circumvent the Website's security procedures. You may not use the Website in any manner that could damage, disable, overburden or impair the Website or any service provided through the Website, or interfere with any other user's use and enjoyment of the Website or any service provided through the Website.
You may not make use of the Website or any service provided through the Website to forge e-mail headers or send bulk unsolicited e-mail messages. Any content we provide or post on the Website may contain errors or inaccuracies, including both typographical and substantive errors.
We reserve the right, in our sole discretion and for any reason, without any obligation or notice requirement, to discontinue, change, improve or correct the content we provide or post on the Website. Any dated content we provide or post on the Website is published as of its date only and we have no responsibility to update or amend any such content.
It is your sole responsibility to evaluate the accuracy, completeness or usefulness of any content provided or posted on the Website. Your Use of Content Contained on the Website Except where otherwise expressly noted or contemplated, all content provided or posted on the Website is being made available to you for the purpose of Huntington's disease related research activities.
Disclaimer of Warranties, Not a Substitute for Medical Advice and Limitation of Liability? THE WEBSITE IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS.
WE AND OUR AFFILIATES AND AGENTS MAKE NO REPRESENTATIONS, WARRANTIES OR CONDITIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR OTHERWISE, AS TO THE OPERATION OF THE WEBSITE, OR THE ACCURACY, TIMELINESS OR COMPLETENESS OF CONTENT OR SERVICES INCLUDED ON THE WEBSITE.
YOU EXPRESSLY AGREE THAT YOUR USE OF THE WEBSITE AND ANY CONTENT OR SERVICES INCLUDED ON THE WEBSITE IS AT YOUR SOLE RISK.
ALL CONTENT INCLUDED ON THE WEBSITE, SUCH AS TEXT, TREATMENTS, DATA, DOSAGES, OUTCOMES, CHARTS, PATIENT PROFILES, GRAPHICS, PHOTOGRAPHS, IMAGES, ADVICE, MESSAGES, FORUM POSTINGS AND ANY OTHER CONTENT PROVIDED ON THE WEBSITE ARE FOR INFORMATIONAL PURPOSES ONLY AND ARE NOT A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE OR TREATMENT.
YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROVIDER WITH ANY QUESTIONS YOU MAY HAVE REGARDING YOUR HEALTH. NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY IN SEEKING IT BECAUSE OF SOMETHING YOU HAVE READ ON THIS WEBSITE. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY.
WE DO NOT RECOMMEND OR ENDORSE ANY SPECIFIC TESTS, PHYSICIANS, PRODUCTS, PROCEDURES, OPINIONS, OR OTHER CONTENT THAT MAY BE MENTIONED ON THE WEBSITE.
YOU EXPRESSLY AGREE THAT NEITHER WE NOR OUR AFFILIATES AND AGENTS ARE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING OR RESULTING FROM YOUR USE OF THE WEBSITE OR ANY CONTENT OR SERVICES INCLUDED ON THE WEBSITE, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES. Revision No.
004 (Effective 9/08/2016) Collection of Information and Use If you join our mailing list, we collect some information that can be directly associated with you. We call this information "Personal Information" and it includes your name, title and email address and the name of the company or research institution with which you are affiliated.
You may modify your Personal Information at any time by following the update profile/email address links at the end of any email we send you. By joining our mailing list, you have granted us permission to use your Personal Information to send you emails ("opt-in") relating to our activities and Huntington's disease related research and information.
If you have received an email from us, our records indicate that you joined our mailing list. Because we respect your time and attention, we make every effort to control the frequency of our emails. You may revoke the permission you have given us to use your Personal Information to send you emails ("opt-out") by following the instructions set out in our e-mails.
If you believe you have received unwanted, unsolicited email from us sent via the Website or purporting to be sent via the Website, please forward a copy of that email to > . Privacy and Sharing of Your Personal Information We maintain a variety of physical, electronic and procedural safeguards to protect your Personal Information.
As mentioned above, it is our general policy to restrict access to Personal Information to our employees and agents. The Website may have links to other websites that we do not control. You should know that we have no control over the content, privacy policies or security of any of these websites you elect to visit or interact with.
Furthermore, we are not responsible for the content, privacy policies or security of any of these websites you elect to visit or interact with and you should check those policies on such websites. Browser Information Collected on the Website We log IP addresses, which are the locations of computers or networks on the Internet, and analyze them in order to improve the utility of the Website.
We also collect aggregate numbers of page hits in order to track the popularity of certain pages and improve the utility of the Website. We do not gather, request, record, require, collect or track any users' Personal Information through these processes. Web Beacons can be refused when delivered via email.
If you do not wish to receive Web Beacons via email, you will need to disable HTML images or refuse HTML (select Text only) emails via your email software. Revision No. 003 (Effective 11/01/2015) Click to read a letter from Robert Pacifici, CHDI CSO, regarding COVID-19
© 2026 Granted AI